Discover
CGEM
Cullinan Therapeutics, Inc.
17.28
2 x 13.20
2 x 22.19
bid
ask
-
0.93
5.11%
2 @ 04:53 AM
17.54 +0.26 (1.48%)
| Ytd | 66.96% | |
| 1y | 126.18% |
17.27
day range
18.47
5.68
52 week range
19.43
| Open | 18.05 | Prev Close | 18.21 | Low | 17.27 | High | 18.47 | Mkt Cap | 1.06B |
| Vol | 737.53K | Avg Vol | 1.08M | EPS | -3.37 | P/E | N/A | Forward P/E | -6.84 |
| Beta | 0.01 | Short Ratio | 6.74 | Inst. Own | 107.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 14.94 | 200-d Avg | 11.86 | 1yr Est | 31.55 |
CGEM News
benzinga.com
Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $37 Price Target
Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform
benzinga.com
Cullinan Therapeutics Reports Clinical Data And Outlines Global Clinical Development Plans For CLN-9
CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both
benzinga.com
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with
benzinga.com
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in
benzinga.com
Reported Saturday, Cullinan's CLN-978 Delivers Deep B Cell Depletion And Clinical Remissions In SLE
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and